PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial thera […]
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at two upcoming investor conferences in the month of September. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company’s website at www.celgene.c […]
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen (Euronext:IPN; ADR:IPSEY) today announced that Cynthia Schwalm has been named President and CEO of Ipsen N.A., responsible for all commercial and medical affairs operations throughout the region. She will assume oversight of all areas supporting the North American Business and will report to Pierre Boulud, EVP of S […]
PRINCETON, N.J. and NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that they will present 14 abstracts (oral and poster presentations) at the ESC Congress 2014, organized by the European Society of Cardiology, to be held August 30 to September 4 in Barcelona, Spain. The new clinical trial data an […]
MORRISTOWN, N.J. & HONOLULU--(BUSINESS WIRE)--Capsugel and Cardax announce collaboration to develop proprietary astaxanthin products for the consumer health market with lipid-based formulations for improved oral bioavailability.
SUMMIT, N.J.--(BUSINESS WIRE)--STUDY IN THE JOURNAL OF CLINICAL ONCOLOGY REPORTS PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RECEIVING ORAL REVLIMID WITH STANDARD R-CHOP ACHIEVED 98% OVERALL RESPONSE RATE AND 80% COMPLETE
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Insmed Incorporated (Nasdaq:INSM) announced the closing of a $115.1 million underwritten public offering of 10,235,000 shares of common stock, including 1,335,000 shares of common stock which were issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a price of $11.25 per share […]
BASKING RIDGE, N.J.--(BUSINESS WIRE)--electroCore has appointed Piper Jaffray to assist in discussions with pharma companies on commercialization of its non-invasive vagus nerve (nVNS) stimulation therapy.